Combination bNAb therapy may offer a future alternative to daily ART for people living with HIV

By | June 2, 2022
Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a small study published today in the journal Nature.